{
 "query": "finerenone",
 "ingredient": "finerenone",
 "slug": "finerenone",
 "rxcui": "2562811",
 "brands": [
  "Kerendia"
 ],
 "names": [
  "finerenone"
 ],
 "classes": [
  {
   "id": "C03DA",
   "name": "Aldosterone antagonists"
  }
 ],
 "alternatives": [
  "canrenoate potassium",
  "canrenone",
  "eplerenone",
  "spironolactone"
 ],
 "label": {},
 "faers": {
  "total": 2960,
  "serious": 2018,
  "death": 217,
  "hospitalization": 566,
  "primary_suspect": 2949,
  "top_reactions": [
   [
    "Glomerular Filtration Rate Decreased",
    308
   ],
   [
    "Hyperkalaemia",
    261
   ],
   [
    "Blood Creatinine Increased",
    226
   ],
   [
    "Blood Potassium Increased",
    180
   ],
   [
    "Death",
    178
   ],
   [
    "Renal Impairment",
    140
   ],
   [
    "Dizziness",
    116
   ],
   [
    "Acute Kidney Injury",
    104
   ],
   [
    "Nausea",
    96
   ],
   [
    "Diarrhoea",
    92
   ],
   [
    "Off Label Use",
    83
   ],
   [
    "Hypotension",
    79
   ],
   [
    "Urine Albumin/Creatinine Ratio Increased",
    77
   ],
   [
    "Fatigue",
    74
   ],
   [
    "Dyspnoea",
    63
   ]
  ],
  "by_year": {
   "2016": 1,
   "2017": 1,
   "2021": 56,
   "2022": 393,
   "2023": 531,
   "2024": 634,
   "2025": 809,
   "2026": 535
  },
  "by_year_primary": {
   "2016": 1,
   "2017": 1,
   "2021": 56,
   "2022": 391,
   "2023": 528,
   "2024": 631,
   "2025": 807,
   "2026": 534
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 2,
  "nda": 1,
  "anda": 0,
  "first_approval": "20210709",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 0,
  "labeling_recent": 0,
  "sponsors": [
   "APOTEX INC",
   "BAYER HLTHCARE"
  ],
  "unapproved": false,
  "first_approval_fmt": "07/09/2021"
 },
 "trials": {
  "total": 108,
  "completed": 38,
  "terminated": 3,
  "with_results": 8,
  "industry": 49,
  "phase3": 22,
  "results_share": 0.21052631578947367,
  "terminated_share": 0.027777777777777776
 },
 "pubmed": {
  "rct": 95,
  "meta": 27,
  "recent_rct": 85,
  "cochrane": []
 },
 "payments": {
  "year": "2024",
  "usd": 5523572.42,
  "records": 117647,
  "by_name": [
   [
    "Kerendia",
    5523572.42
   ]
  ],
  "names_checked": [
   "finerenone",
   "Kerendia"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 403577,
  "beneficiaries": 88208,
  "spend": 396302773.23,
  "by_brand": [
   {
    "brand": "Kerendia",
    "claims": 403577,
    "per_claim": 981.97561613,
    "is_generic": false
   }
  ],
  "per_claim": 981.9756161277774
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": false,
  "status": "",
  "name": "",
  "matched": null,
  "stewardship": []
 },
 "exposure": {
  "years": [
   "2024",
   "2025",
   "2026"
  ],
  "reports_recent": 1972,
  "fills": 403577,
  "per_million": 4886.304224472653,
  "ratio": 1.7646778233457454,
  "median": 2768.949753790441
 },
 "scores": {
  "safety": {
   "score": 95,
   "letter": "A",
   "why": [
    "4,886 FDA reports naming it as the suspect drug per million Medicare fills, 1.8x the median drug on this site (-5)",
    "Death share in reports is near or below the FAERS average (0.8x)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 46,
   "letter": "F",
   "why": [
    "95 randomized trials and 27 systematic reviews/meta-analyses indexed in PubMed",
    "No Cochrane review found (-5)",
    "Only 21% of completed registered trials posted results (-15)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 90,
   "letter": "A",
   "why": [
    "No recalls on record since 2016",
    "Approved within the last 5 years: long-term safety is not yet known (-10)"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 70,
   "letter": "C",
   "why": [
    "Pharma paid doctors $5,523,572 tied to this drug last year (-30)",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 70,
   "letter": "C",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "4 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 76,
 "grade": "B",
 "questions": [
  "The most-reported problems in FDA's adverse event data are glomerular filtration rate decreased, hyperkalaemia, blood creatinine increased, blood potassium increased. How would we recognize and handle those?",
  "Why this one over canrenoate potassium, canrenone, eplerenone? What would make you pick one of those instead?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "The manufacturer pays physicians heavily to promote this drug. Have you received anything from them?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}